Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35462030)

  • 1. The HER family as therapeutic targets in colorectal cancer.
    Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
    Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
    Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
    J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
    Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
    J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of human epidermal growth factor receptor family in pulmonary lymphangioleiomyomatosis.
    Kobayashi K; Miki Y; Saito R; Adachi K; Seyama K; Okada Y; Sasano H
    Hum Pathol; 2018 Nov; 81():121-130. PubMed ID: 30030119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.
    Kurozumi S; Yamaguchi Y; Matsumoto H; Inoue K; Kurosumi M; Oyama T; Horiguchi J; Fujii T; Shirabe K
    Med Mol Morphol; 2019 Jun; 52(2):90-98. PubMed ID: 30259117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of human epidermal growth factor receptors for patient selection and response monitoring - From PET imaging and beyond.
    Pereira PMR; Abma L; Henry KE; Lewis JS
    Cancer Lett; 2018 Apr; 419():139-151. PubMed ID: 29414302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
    Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer.
    Yun S; Kwak Y; Nam SK; Seo AN; Oh HK; Kim DW; Kang SB; Lee HS
    Cancer Res Treat; 2018 Oct; 50(4):1351-1361. PubMed ID: 29361822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HER proteins in cancer therapy and the role of the non-target HER3.
    Hsieh AC; Moasser MM
    Br J Cancer; 2007 Aug; 97(4):453-7. PubMed ID: 17667926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
    Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
    Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
    Sergina NV; Rausch M; Wang D; Blair J; Hann B; Shokat KM; Moasser MM
    Nature; 2007 Jan; 445(7126):437-41. PubMed ID: 17206155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
    Monsey J; Shen W; Schlesinger P; Bose R
    J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.
    Claus J; Patel G; Ng T; Parker PJ
    Biochem Soc Trans; 2014 Aug; 42(4):831-6. PubMed ID: 25109965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
    Kong A; Calleja V; Leboucher P; Harris A; Parker PJ; Larijani B
    PLoS One; 2008 Aug; 3(8):e2881. PubMed ID: 18682844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
    PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.
    Sun M; Behrens C; Feng L; Ozburn N; Tang X; Yin G; Komaki R; Varella-Garcia M; Hong WK; Aldape KD; Wistuba II
    Clin Cancer Res; 2009 Aug; 15(15):4829-37. PubMed ID: 19622585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
    Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
    Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.
    Shankaran H; Zhang Y; Tan Y; Resat H
    PLoS Comput Biol; 2013; 9(8):e1003201. PubMed ID: 23990774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.